beractant
Trade name: survanta
Small moleculeapprovedOrphan Drug FDA
Approved
Jul 1, 1991
Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract, to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins. As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome. Survanta is manufactured by Abbvie. — Wikipedia
Clinical trial activity
17 trials · 43 clinical orgs · 1 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
2
Phase 4
3
Earliest trial started Jan 1, 1991 (NCT01203358)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Bronchopulmonary Dysplasia · Phase 2/Phase 3
- Burkitt Lymphoma · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Verrucous · Phase 2
- Cardiovascular Diseases · Phase 1
- Coronary Artery Disease · Phase 4
- Ductus Arteriosus, Patent · Phase 4
- Head and Neck Neoplasms · Phase 1
- Hodgkin Disease · Phase 2
- Infant, Low Birth Weight · Phase 2/Phase 3
- Infant, Newborn · Phase 2/Phase 3
- Infant, Premature · Phase 2/Phase 3
- Infant, Premature, Diseases · Phase 4
- Infant, Small for Gestational Age · Phase 2/Phase 3
- Leukemia, Eosinophilic, Acute · Phase 2
- Leukemia, Hairy Cell · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Leukemia, Neutrophilic, Chronic · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 2
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Nausea · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Neuroblastoma · Phase 2
- Ovarian Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Primary Myelofibrosis · Phase 2
- Respiratory Distress Syndrome · Phase 4
- Respiratory Insufficiency · Phase 4
- Sezary Syndrome · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Testicular Neoplasms · Phase 2
- Tongue Neoplasms · Phase 2
Mechanism of action
- Unspecified targetOTHER
Surfactant agent
Replaces endogenous surfactant in case of deficiency; endogenous pulmonary surfactant lower surface tension at the air-liquid of the alveolar surfaces
- Unspecified targetSurfactant
Surfactant
Replaces endogenous surfactant in case of deficiency; endogenous pulmonary surfactant lower surface tension at the air-liquid of the alveolar surfaces
Approval history
- approvedJul 1, 1991
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaBeractant ↗
- ChEMBLCHEMBL1201624 ↗
Also known as
- a-60386x
- beractant
- beractant
- beractant
- beractant
- beractant
- beractant
- beractant
- beractant
- beractant
- surfactant-ta
- survanta
- survanta
- survanta
- survanta
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02774044 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2016 | All India Institute of Medical Sciences, Azad University, Chacha Nehru Bal Chikitsalaya, New Delhi, Government Medical College, Chandigarh, Hospital for Children, Chennai, Jawaharlal Institute of Postgraduate Medical Education and Research, King Edward Memorial Hospital, Mumbai, Lady Hardinge Medical College, Lokmanya Tilak Municipal Medical College, Postgraduate Institute of Medical Education and Research, Rajiv Gandhi University of Health Sciences, Wellcome Trust |
| NCT01941524 | Phase 4 | Sep 1, 2013 | Poznan University |
| NCT01740154 | N/A | Sep 1, 2012 | Case Western Reserve University, National Cancer Institute (NCI), University of Rochester |
| NCT01537354 | N/A | Jun 1, 2012 | Rafael Pharmaceuticals Inc., University of Michigan |
| NCT01852461 | N/A | Aug 1, 2011 | Dr. Sami Ulus Children's Hospital, Sami Ulus Maternity and Childrens Hospital |
| NCT01342757 | N/A | Dec 1, 2010 | Emory University, National Cancer Institute (NCI) |
| NCT01069003 | Phase 4 | Apr 1, 2010 | Fletcher Allen Hospital, Harvard University, Medtronic |
| NCT01860014 | N/A | Mar 1, 2010 | Dr. Sami Ulus Children's Hospital, Zekai Tahir Burak Hospital |
| NCT01051401 | Phase 1 | Jan 1, 2010 | National Cancer Institute (NCI), Wake Forest University |
| NCT01036412 | Phase 1 | Dec 1, 2009 | University of Texas at Houston |
| NCT02007200 | Phase 2 | Jul 1, 2009 | National Cancer Institute (NCI), University of Michigan |
| NCT00795769 | Phase 2 | Aug 8, 2008 | University of Washington |
| NCT01031953 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2008 | National Cancer Institute (NCI), Oregon Health and Science University |
| NCT01504932 | N/A | Feb 23, 2007 | Ohio State University |
| NCT00343863 | N/A | Jan 1, 2006 | National Cancer Institute (NCI), University of Washington |
| NCT00767039 | Phase 4 | Jan 1, 2005 | Boston University, Merck |
| NCT01203358 | Phase 2/Phase 3 (Phase 3) | Jan 1, 1991 | Case Western Reserve University, Emory University, George Washington University, Indiana University, National Institute of Child Health and Human Development (NICHD), Stanford University, The University of Texas, Dallas, University of Cincinnati, University of Miami, University of New Mexico, University of Tennessee, University of Vermont, Wayne State University |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (43)
43 organizations
Page 1 / 3